As the first generation of oral antiangiogenesis drug created in China, apatinib which targets mainly at VEGFR-2 has a significant effect on the treatment of the advanced gastric carcinoma, significantly prolonging overall survival time (OS) of the advanced gastric cancer patients who failed in the second-line treatment. The gene discussed is KDR; the disease is gastric cancer.